<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03760679</url>
  </required_header>
  <id_info>
    <org_study_id>341-SBKAEK</org_study_id>
    <nct_id>NCT03760679</nct_id>
  </id_info>
  <brief_title>Laryngeal Mask Supreme and I-Gel in Edentulate Geriatric Patients</brief_title>
  <official_title>Comparison of Laryngeal Mask Supreme and I-Gel in Edentulate Geriatric Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dokuz Eylul University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dokuz Eylul University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary aim of this study is to evaluate ease and duration of placing Laryngeal Mask&#xD;
      Supreme (LM) and applying I-gel in geriatric patients without teeth. The secondary aim is to&#xD;
      compare their effects on ventilation parameters.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective, randomized and double-blind study, aged from 18 to 65 years undergoing elective&#xD;
      laparoscopic gynecological surgery.&#xD;
&#xD;
      The patients are randomly assigned to 2 groups:&#xD;
&#xD;
        -  Group 1: i-gel&#xD;
&#xD;
        -  Group 2: laryngeal mask airway - Supreme&#xD;
&#xD;
      Procedure:&#xD;
&#xD;
      The investigation protocol contains the following sections:&#xD;
&#xD;
        1. Induction of anaesthesia: Preoxygenation will be provided at 6 Liter/min oxygen for&#xD;
           three minutes by using a facial mask. After anesthesia induction with fentanyl 1-2 μg/kg&#xD;
           and propofol 1-2 mg/kg (12), mask ventilation will be applied with 100% oxygen.&#xD;
&#xD;
        2. Bispectral index values will be held between 40-60.Bispectral index values will be&#xD;
           within this interval by increasing or decreasing propofol infusion by 1 mg/kg after&#xD;
           additional bolus dose of propofol (1 mg/kg).&#xD;
&#xD;
        3. Insertion of the airway device. The size of the airway device used is based on the&#xD;
           manufacturers' recommendations. All devices are deflated a lubricated prior to use. Once&#xD;
           inserted, the cuff is be inflated with a manometer up to 60 cm H20 Data recorded: size&#xD;
           of airway device, time an number of attempts.&#xD;
&#xD;
        4. Maintenance of anesthesia will be achieved with sevoflurane 1,5-2,5% in a mixture of 50%&#xD;
           O2/ 50% nitrogen protoxide. Sevoflurane concentrations will be adjusted to keep&#xD;
           bispectral index values at 40-60.&#xD;
&#xD;
        5. Measurement of airway seal pressure (oropharyngeal leak pressure (OLP): at baseline, and&#xD;
           two minutes after the airway tool is placed, every 15 minutes until the operation ends&#xD;
           and before the airway tool is removed.&#xD;
&#xD;
        6. Ventilatory mechanics and parameters and hemodynamic parameters are measured at&#xD;
           baseline, and two minutes after the airway tool is placed, every 15 minutes until the&#xD;
           operation ends and before the airway tool is removed.&#xD;
&#xD;
        7. Perioperative complications: Cough, vomiting, laryngeal spasm, laryngeal Stridor&#xD;
&#xD;
        8. Removal of the airway device: Presence of blood - 3 level grading (1:no blood; 2: trace&#xD;
           amounts of blood; 3: clear amounts of blood). Complications: sore throat (visual&#xD;
           analogue scale :10-point scale), dysphonia (yes/no), dysphagia (yes/no).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2018</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Airway Seal Pressure Values</measure>
    <time_frame>intraoperative</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>insertion time</measure>
    <time_frame>intraoperative</time_frame>
    <description>placement of airway device (second)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>sore throat</measure>
    <time_frame>postoperative 1th hour and 24th hour</time_frame>
    <description>postoperative pharyngolaryngeal morbidity- (Visual Analog Pain Scale is a unidimensional measure of pain intensity ), (&quot;no pain&quot; (score of 0) and &quot;pain as bad as it could be&quot; or &quot;worst imaginable pain&quot; (score of 100 [100-mm scale])</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>dysphagia</measure>
    <time_frame>postoperative 1th hour and 24th hour</time_frame>
    <description>postoperative pharyngolaryngeal morbidity- dysphagia (yes/no)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>dysphonia</measure>
    <time_frame>postoperative 1th hour and 24th hour</time_frame>
    <description>postoperative pharyngolaryngeal morbidity- dysphonia (yes/no)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">124</enrollment>
  <condition>Airway Morbidity</condition>
  <arm_group>
    <arm_group_label>Laryngeal mask Supreme</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Device: Laryngeal mask Supreme</description>
  </arm_group>
  <arm_group>
    <arm_group_label>i-gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Device: i-gel</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Laryngeal mask Supreme evaluation</intervention_name>
    <description>Device: Laryngeal mask Supreme evaluation</description>
    <arm_group_label>Laryngeal mask Supreme</arm_group_label>
    <other_name>Device: Laryngeal mask Supreme evaluation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>i-gel evaluation</intervention_name>
    <description>Device: i-gel evaluation</description>
    <arm_group_label>i-gel</arm_group_label>
    <other_name>Device: i-gel evaluation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  American Society of Anesthesiologists Classification I-III patients&#xD;
&#xD;
          -  patients aged 65 years and older&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  having teeth or fixed prosthesis&#xD;
&#xD;
          -  having a pathology of the neck or the upper respiratory tract&#xD;
&#xD;
          -  having a risk of regurgitation of gastric content/ aspiration (prior upper&#xD;
             gastrointestinal system surgery, hiatus hernia, gastrointestinal reflux, history of&#xD;
             peptic ulcer and full stomach)&#xD;
&#xD;
          -  history or possibility of difficult airway (history of impossible intubation,&#xD;
             mallampati score of 3-4, sternomental distance of shorter than 12 cm, thyromental&#xD;
             distance of shorter than 6cm, head extension of lower than 90 degrees and mouth&#xD;
             opening of lower than 1.5 cm)&#xD;
&#xD;
          -  lower pulmonary compliance or higher airway resistance (morbid obesity -BMI&gt;35kg/m2-&#xD;
             and pulmonary disease) Each patient will be examined preoperatively and American&#xD;
             Society of Anesthesiologists Classification scores and mallampati scores will be&#xD;
             recorded. Standard monitoring (ECG, pulse oximetry and noninvasive blood pressure&#xD;
             measurement) and bispectral index monitoring will be performed in each patient before&#xD;
             induction of anesthesia in the surgical room.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sibel Büyükçoban</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dokuz Eylül University, School of Medicine, Department of Anesthesiology and Intensive Care</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Şule Özbilgin</last_name>
    <phone>05055252901</phone>
    <email>ozbilginsule@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sibel Büyükçoban</last_name>
    <email>sibelbuyukcoban@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Şule Özbilgin</name>
      <address>
        <city>İzmir</city>
        <zip>35340</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Şule Özbilgin</last_name>
      <phone>5055252901</phone>
      <email>ozbilginsule@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Sibel Büyükçoban, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 30, 2018</study_first_submitted>
  <study_first_submitted_qc>November 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 30, 2018</study_first_posted>
  <last_update_submitted>August 18, 2020</last_update_submitted>
  <last_update_submitted_qc>August 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dokuz Eylul University</investigator_affiliation>
    <investigator_full_name>Sule Ozbilgin</investigator_full_name>
    <investigator_title>Investigator</investigator_title>
  </responsible_party>
  <keyword>laryngeal mask</keyword>
  <keyword>geriatric</keyword>
  <keyword>patient</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chlorhexidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

